Northern Development is a Norwegian/Australian based company developing a next generation heart assist device, targeting a major population Heart Failure patients who currently have no treatment option, the HFpEF population. This population, HFpEF or diastolic heart failure, represents a total sales potential of more than EUR 5 billions. The PulseVad technlogy will also represent major benefits for the current HFrEF market, a market today dominated by Medtronic and Abbott. The HFpEF population is fast growing and is expected to pass the current LVAD population (HFrEF/systoiic heart failure), HFrEF, by 2020 and where the younger population is growing fastest. Northern Development has developed PulseVad, a new, sensor-based pump, allowing for treatment of HFpEF patients, as the first company. Pre Clinicals estimated to start Q3 2019, First in Man planned for December 2020. PulseVad will be the first assist device to enter the HFpEF market, and have several technological break throughs including intelligent sensors, minimal invasive implantation system, implantable controller and offers adaptive blood supply for the patients. The key components in system have finalized prototypes and been tested in bench and animal models. Valuation of the company is expected to be high and exit options multiple by 2021,Northern Development is a Norwegian/Australian based company developing a next generation heart assist device, targeting a major population Heart Failure patients who currently have no treatment option, the HFpEF population. This population, HFpEF or diastolic heart failure, represents a total sales potential of more than EUR 5 billions. The PulseVad technlogy will also represent major benefits for the current HFrEF market, a market today dominated by Medtronic and Abbott. The HFpEF population is fast growing and is expected to pass the current LVAD population (HFrEF/systoiic heart failure), HFrEF, by 2020 and where the younger population is growing fastest. Northern Development has developed PulseVad, a new, sensor-based pump, allowing for treatment of HFpEF patients, as the first company. Pre Clinicals estimated to start Q3 2019, First in Man planned for December 2020. PulseVad will be the first assist device to enter the HFpEF market, and have several technological break throughs including intelligent sensors, minimal invasive implantation system, implantable controller and offers adaptive blood supply for the patients. The key components in system have finalized prototypes and been tested in bench and animal models. Valuation of the company is expected to be high and exit options multiple by 2021

南极磷虾是全球最纯净的海洋价值，是世界最大的优质蛋白资源。本项目响应国家海洋战略，开发利用南极磷虾，抢占生命科技至高点，打造品牌，实现资源价值。,南极磷虾是全球最纯净的海洋价值，是世界最大的优质蛋白资源。本项目响应国家海洋战略，开发利用南极磷虾，抢占生命科技至高点，打造品牌，实现资源价值。

Over 10 million people worldwide have Parkinson's disease (PD). 89% of people with PD have a speech problem (hypokinetic dysarthria) where people speak so softly they cannot be understood and can no longer communicate and stay socially active. SpeechVive is a wearable device which gives IMMEDIATE, NOTICEABLE, and LASTING improvement to over 75% of people who use the device. SpeechVive was developed at Purdue University and has published clinical trials demonstrating efficacy. SpeechVive has been on the market in the U.S. for 2 1/2 years, has revenue of over $300,000, 80% of revenue is through the VA medical centers. SpeechVive has sold over 300 devices to date.,Over 10 million people worldwide have Parkinson's disease (PD). 89% of people with PD have a speech problem (hypokinetic dysarthria) where people speak so softly they cannot be understood and can no longer communicate and stay socially active. SpeechVive is a wearable device which gives IMMEDIATE, NOTICEABLE, and LASTING improvement to over 75% of people who use the device. SpeechVive was developed at Purdue University and has published clinical trials demonstrating efficacy. SpeechVive has been on the market in the U.S. for 2 1/2 years, has revenue of over $300,000, 80% of revenue is through the VA medical centers. SpeechVive has sold over 300 devices to date.

在世界范围内，有10-24%的人口患有非酒精性脂肪肝病(NAFLD)，已成为一种流行疾病。随着肥胖，高血压和糖尿病的患者增加，以及代谢，营养，药物和食品安全等，我国将出现更多非酒精性脂肪肝炎（NASH）的患者。目前还没有治疗非酒精性脂肪肝的专门药（目前尚无特效药物）。患者只有通过控制饮食，减肥和锻炼来减缓病征。预计到2020年这方面的全球市场将达到700亿美元。 我们团队研制的化学1.1类新药RJN-801通过初步临床前期的动物实验证明， 它具有治疗非酒精性脂肪肝炎和减肥疗效。本项目在成药后将成为治疗非酒精性脂肪肝炎的一线药物。,在世界范围内，有10-24%的人口患有非酒精性脂肪肝病(NAFLD)，已成为一种流行疾病。随着肥胖，高血压和糖尿病的患者增加，以及代谢，营养，药物和食品安全等，我国将出现更多非酒精性脂肪肝炎（NASH）的患者。目前还没有治疗非酒精性脂肪肝的专门药（目前尚无特效药物）。患者只有通过控制饮食，减肥和锻炼来减缓病征。预计到2020年这方面的全球市场将达到700亿美元。 我们团队研制的化学1.1类新药RJN-801通过初步临床前期的动物实验证明， 它具有治疗非酒精性脂肪肝炎和减肥疗效。本项目在成药后将成为治疗非酒精性脂肪肝炎的一线药物。

MediSieve is a medical device therapeutics company developing “magnetic blood filtration”, a revolutionary method of treating blood-borne diseases by removing pathogens directly from a patient’s bloodstream. Practically any component can be specifically targeted and removed, providing a platform technology that could treat a huge range of conditions, accessing several billion-dollar markets. The first applications are in sepsis, leukaemia and malaria. MediSieve products include magnetic particles, which bind specific targets in blood, and a magnetic filter which captures and removes the particles and targets. The filter will undergo clinical trials in Q2 2019. The particles are currently being validated in vitro.,MediSieve is a medical device therapeutics company developing “magnetic blood filtration”, a revolutionary method of treating blood-borne diseases by removing pathogens directly from a patient’s bloodstream. Practically any component can be specifically targeted and removed, providing a platform technology that could treat a huge range of conditions, accessing several billion-dollar markets. The first applications are in sepsis, leukaemia and malaria. MediSieve products include magnetic particles, which bind specific targets in blood, and a magnetic filter which captures and removes the particles and targets. The filter will undergo clinical trials in Q2 2019. The particles are currently being validated in vitro.

The aim of this project is to develop a medical-grade temperature/activity monitor that can monitor thermoregulatory, biomechanical and physiological responses of an individual in real time. The proposed research aims to protect the health of athletes and officials against heat stroke during the Tokyo 2020 Olympic Games, the second highest cause of fatalities in sport. This project will have important legacy implications beyond the protection of the health of athletes in the Olympics and will include applications in the emergency services, the military and the health and leisure industry.,The aim of this project is to develop a medical-grade temperature/activity monitor that can monitor thermoregulatory, biomechanical and physiological responses of an individual in real time. The proposed research aims to protect the health of athletes and officials against heat stroke during the Tokyo 2020 Olympic Games, the second highest cause of fatalities in sport. This project will have important legacy implications beyond the protection of the health of athletes in the Olympics and will include applications in the emergency services, the military and the health and leisure industry.